Metitepine: Difference between revisions
CSV import |
CSV import |
||
| Line 23: | Line 23: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:Metitepine.svg|Metitepine | |||
File:Metitepine synthesis.svg|Metitepine synthesis | |||
</gallery> | |||
Latest revision as of 01:29, 20 February 2025
Metitepine (also known as methiothepin) is a drug that acts as a non-selective 5-HT receptor antagonist plus alpha-adrenergic antagonist. It has been used in the research of various neurological disorders, including depression and schizophrenia.
Pharmacology[edit]
Metitepine acts as an antagonist at multiple subsets of the 5-HT receptor, including 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT1F, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT3, 5-HT5A, 5-HT6, and 5-HT7. It also has high affinity for the alpha-adrenergic receptor, where it acts as an antagonist.
Clinical Use[edit]
While Metitepine has been used in the research of various neurological disorders, it is not commonly used in clinical practice due to its broad spectrum of action and potential for side effects. It has been studied in the treatment of depression and schizophrenia, but more research is needed to determine its efficacy and safety in these conditions.
Side Effects[edit]
Potential side effects of Metitepine include dizziness, nausea, vomiting, and hypotension. Due to its action at the alpha-adrenergic receptor, it may also cause orthostatic hypotension.
